<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26471197</article-id>
      <article-id pub-id-type="pmc">4608352</article-id>
      <article-id pub-id-type="publisher-id">1169</article-id>
      <article-id pub-id-type="doi">10.1186/s12879-015-1169-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ebola virus disease complicated with viral interstitial pneumonia: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Petrosillo</surname>
            <given-names>Nicola</given-names>
          </name>
          <address>
            <email>nicola.petrosillo@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nicastri</surname>
            <given-names>Emanuele</given-names>
          </name>
          <address>
            <email>emanuele.nicastri@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lanini</surname>
            <given-names>Simone</given-names>
          </name>
          <address>
            <email>simone.lanini@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capobianchi</surname>
            <given-names>Maria Rosaria</given-names>
          </name>
          <address>
            <email>maria.capobianchi@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Di Caro</surname>
            <given-names>Antonino</given-names>
          </name>
          <address>
            <email>antonino.dicaro@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Antonini</surname>
            <given-names>Mario</given-names>
          </name>
          <address>
            <email>mario.antonini@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Puro</surname>
            <given-names>Vincenzo</given-names>
          </name>
          <address>
            <email>vincenzo.puro@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lauria</surname>
            <given-names>Francesco Nicola</given-names>
          </name>
          <address>
            <email>francesco.lauria@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shindo</surname>
            <given-names>Nakono</given-names>
          </name>
          <address>
            <email>shindon@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magrini</surname>
            <given-names>Nicola</given-names>
          </name>
          <address>
            <email>magrinin@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kobinger</surname>
            <given-names>Gary P.</given-names>
          </name>
          <address>
            <email>gary.kobinger@phac-aspc.gc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Ippolito</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <address>
            <email>giuseppe.ippolito@inmi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <collab>INMI EBOV Team</collab>
        </contrib>
        <aff id="Aff1"><label/>National Institute for Infectious Diseases Lazzaro Spallanzani-INMI IRCCS, Rome, Italy </aff>
        <aff id="Aff2"><label/>Pandemic and Epidemic Diseases Department, World Health Organization, Geneva, Switzerland </aff>
        <aff id="Aff3"><label/>Essential Medicines and Health Products Department, World Health Organization, Geneva, Switzerland </aff>
        <aff id="Aff4"><label/>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB Canada </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>432</elocation-id>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Petrosillo et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>In the current Ebola epidemic in Western Africa, many healthcare workers have become infected. Some of these have been medically evacuated to hospitals in Europe and the USA. These clinical experiences provide unique insights into the course of Ebola virus disease under optimized condition within high level isolation units.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 50-year-old Caucasian male physician contracted Ebola virus diseases in Sierra Leone and was medically evacuated to Italy. Few days after the admission the course of the illness was characterized by severe gastro-intestinal symptoms followed by respiratory failure, accompanied by pulmonary infiltration and high Ebola viral load in the bronchial aspirate and Plasmodium vivax co-infection. The patient received experimental antiviral therapy with favipiravir, convalescent plasma and ZMAb. Ebola viral load started to steadily decrease in the blood after ZMAb administration and became undetectable by day 19 after admission, while it persisted longer in urine samples. No temporal association was observed between viral load decay in plasma and administration of favipiravir. The patient completely recovered and was discharged 39&#xA0;days after admission.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This is the first case of Ebola-related interstitial pneumonia documented by molecular testing of lung fluid specimens. This reports underlines the pivotal role of fluid replacement and advanced life support with mechanical ventilation in the management of patients with Ebola virus diseases respiratory failure. Beside our finding indicates a close temporal association between administration of cZMAb and Ebola virus clearance from blood.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/s12879-015-1169-4) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Hemorrhagic fever</kwd>
        <kwd>Ebola</kwd>
        <kwd>Pneumonia, viral</kwd>
        <kwd>Malaria, vivax</kwd>
        <kwd>Immunization, passive</kwd>
        <kwd>Antibodies, monoclonal</kwd>
        <kwd>Favipiravir</kwd>
        <kwd>Fluid therapy</kwd>
        <kwd>Life support care</kwd>
        <kwd>Hospitals, isolation</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Since December 2013, the Ebola virus (EBOV) Makona variant has been gripping Western Africa [<xref ref-type="bibr" rid="CR1">1</xref>]. Over this time the epidemic has exponentially grown and has moved to Europe and North America, with several imported cases and even few clusters of local transmission [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. An unprecedented number of healthcare workers (HCWs) from different countries have been infected, some of whom died [<xref ref-type="bibr" rid="CR4">4</xref>]. In total 26 cases of Ebola virus diseases (EVD), 4 of which fatal [<xref ref-type="bibr" rid="CR5">5</xref>], have been treated in Europe [<xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>] and North America [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] since the beginning of the outbreak.</p>
      <p>Hereby we describe the successful management of a 50-year-old Italian male physician who contracted Ebola virus disease (EVD) while working in an Ebola Treatment Unit in Sierra Leone. The course of infection was complicated by respiratory failure and <italic>Plasmodium vivax</italic> (<italic>P. vivax</italic>) co-infection.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Presenting concerns</title>
        <p>A 50-year-old male physician contracted Ebola virus disease (EVD) while working in Sierra Leone. He had joined the Ebola treatment center on September 2014 and on November 20, he developed a single episode of vomiting, diarrhea and fever (37.5&#xA0;&#xB0;C). He had no history of previous malaria episode and a malaria antigen rapid test was negative. On November 24 he started artemisinine combined therapy, despite the negative rapid test for malaria. On this same day he tested positive to a molecular assay for Ebola virus (EBOV) and was medically evacuated to the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, by an Italian military flight [<xref ref-type="bibr" rid="CR11">11</xref>]. At arrival (November 25) he was febrile and complained with severe fatigue but self-sufficient. He was admitted to a medical high level isolation unit specifically devoted for caring for patients with highly infectious diseases [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
        <p>Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> reports patient&#x2019;s signs and symptoms timeline. Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref> reports EBOV viral load, blood counts and clinical chemistry, respectively. A detailed description of all laboratory assays is reported in Additional file <xref rid="MOESM1" ref-type="media">1</xref>. The timeline of patient&#x2019;s clinical course is reported in Additional file <xref rid="MOESM2" ref-type="media">2.</xref><table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients clinical parameters during hospital stay</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Day</th><th>Place of stay</th><th>Diarrhea a</th><th>fi02 (%)</th><th>S02 (%)</th><th>Fever (&#xB0;C)</th><th>HR (beat/min)</th><th>Vomit (episode)</th><th>BP (mmHg)</th></tr></thead><tbody><tr><td>25/11/2014</td><td>Medical</td><td>Yes</td><td>21</td><td>98</td><td>39.1</td><td>80</td><td>0</td><td>50/100</td></tr><tr><td>26/11/2014</td><td>Medical</td><td>Yes</td><td>50</td><td>95</td><td>38.4</td><td>89</td><td>0</td><td>80/120</td></tr><tr><td>27/11/2014</td><td>Medical</td><td>Yes</td><td>21</td><td>96</td><td>37.4</td><td>60</td><td>0</td><td>90/135</td></tr><tr><td>28/11/2014</td><td>Medical</td><td>Yes</td><td>21</td><td>97</td><td>39.4</td><td>131</td><td>8</td><td>70/120</td></tr><tr><td>29/11/2014</td><td>Medical</td><td>Yes</td><td>40</td><td>95</td><td>39.4</td><td>80</td><td>3</td><td>80/150</td></tr><tr><td>30/11/2014</td><td>Medical</td><td>Yes</td><td>40</td><td>95</td><td>39.1</td><td>70</td><td>3</td><td>90/145</td></tr><tr><td>01/12/2014</td><td>Medical</td><td>Yes</td><td>40</td><td>91</td><td>38.8</td><td>75</td><td>2</td><td>90/150</td></tr><tr><td>02/12/2014</td><td>Medical</td><td>Yes</td><td>50</td><td>90</td><td>39.4</td><td>80</td><td>2</td><td>80/140</td></tr><tr><td>03/12/2014</td><td>Medical</td><td>Yes</td><td>50</td><td>90 b</td><td>38.4</td><td>64</td><td>2</td><td>80/130</td></tr><tr><td>04/12/2014</td><td>ICU</td><td>Yes</td><td>60</td><td>87 c</td><td>37.8</td><td>70</td><td>2</td><td>80/130</td></tr><tr><td>05/12/2014</td><td>ICU</td><td>Yes</td><td>50</td><td>93 c</td><td>37.4</td><td>120</td><td>0</td><td>70/110</td></tr><tr><td>06/12/2014</td><td>ICU</td><td>Yes</td><td>40</td><td>91 c</td><td>39.2</td><td>110</td><td>0</td><td>70/105</td></tr><tr><td>07/12/2014</td><td>ICU</td><td>1300</td><td>40</td><td>92 c</td><td>37.8</td><td>105</td><td>0</td><td>70/115</td></tr><tr><td>08/12/2014</td><td>ICU</td><td>2100</td><td>30</td><td>93 c</td><td>36.5</td><td>95</td><td>0</td><td>65/110</td></tr><tr><td>09/12/2014</td><td>ICU</td><td>3300</td><td>30</td><td>93 d</td><td>37.5</td><td>100</td><td>0</td><td>75/120</td></tr><tr><td>10/12/2014</td><td>ICU</td><td>1700</td><td>35</td><td>92</td><td>38</td><td>95</td><td>0</td><td>85/130</td></tr><tr><td>11/12/2014</td><td>ICU</td><td>1500</td><td>31</td><td>94</td><td>37.8</td><td>95</td><td>0</td><td>80/120</td></tr><tr><td>12/12/2014</td><td>Medical</td><td>1700</td><td>35</td><td>97</td><td>38.1</td><td>110</td><td>2</td><td>90/150</td></tr><tr><td>13/12/2014</td><td>Medical</td><td>1000</td><td>35</td><td>98</td><td>37.4</td><td>110</td><td>1</td><td>80/110</td></tr><tr><td>14/12/2014</td><td>Medical</td><td>500</td><td>28</td><td>98</td><td>36.8</td><td>95</td><td>0</td><td>80/120</td></tr><tr><td>15/12/2014</td><td>Medical</td><td>300</td><td>28</td><td>99</td><td>36.5</td><td>90</td><td>0</td><td>70/110</td></tr><tr><td>16/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.6</td><td>90</td><td>0</td><td>85/130</td></tr><tr><td>17/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.0</td><td>85</td><td>0</td><td>80/120</td></tr><tr><td>18/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.3</td><td>80</td><td>0</td><td>70/110</td></tr><tr><td>19/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.9</td><td>78</td><td>0</td><td>80/120</td></tr><tr><td>20/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>75</td><td>0</td><td>80/120</td></tr><tr><td>21/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>37.0</td><td>70</td><td>0</td><td>70/110</td></tr><tr><td>22/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.4</td><td>70</td><td>0</td><td>90/130</td></tr><tr><td>23/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.6</td><td>70</td><td>0</td><td>80/120</td></tr><tr><td>24/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>75/110</td></tr><tr><td>25/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>80/120</td></tr><tr><td>26/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>70/130</td></tr><tr><td>27/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.4</td><td>70</td><td>0</td><td>80/130</td></tr><tr><td>28/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>90/130</td></tr><tr><td>29/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.4</td><td>70</td><td>0</td><td>70/120</td></tr><tr><td>30/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>80/110</td></tr><tr><td>31/12/2014</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>90/130</td></tr><tr><td>01/01/2015</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>80/120</td></tr><tr><td>02/01/2015</td><td>Medical</td><td>Na</td><td>21</td><td>98</td><td>36.5</td><td>70</td><td>0</td><td>70/110</td></tr></tbody></table><table-wrap-foot><p>a Diarrhea amount was provided in ml between 7 and 15 December while the rectal collector was in place; b: 66&#xA0;% on air (Fi02 21&#xA0;%); c: under mechanical ventilation; d: extubated; na: not any</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>EBOV viral load in different clinical specimen and time of administration of experimental antiviral therapies</p></caption><graphic xlink:href="12879_2015_1169_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Blood counts during hospital stay. ICU= intensive care unit; WBC= white blood cells; Neu.= neutrophils; Lym.=lymphocytes; Mono.= Monocytes; PLTS= platelets; HB= hemoglobin</p></caption><graphic xlink:href="12879_2015_1169_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Clinical chemistry assays during hospital stay (all tests were performed on venous blood specimens). ICU= intensive care unit; GLU= glucose; ALT= alanine transaminase; BIL.= bilirubin; CREA.= creatinine; BUN.= blood urea nitrogen; Na+= sodium ; K+= potassium; INR= international normalized ratio</p></caption><graphic xlink:href="12879_2015_1169_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Clinical findings during hospital stay</title>
        <sec id="Sec5">
          <title>Admission in medical isolation unit</title>
          <p>The patient remained in the medical isolation unit between November 25 and December 4, 2014. Patients&#x2019; clinical presentation was dominated by fever and gastrointestinal symptoms. At arrival he received fluid therapy, empiric antibiotic therapy and favipiravir. On November 26, therapy with convalescent plasma from one survivor of the present EBOV outbreak was given, the administration was followed by retrosternal chest pain, high fever, chills and low oxygen saturation resolving after hydrocortisone and clorfenamine administration. On November 28, a measles-like rash appeared on head, trunk and limbs and was accompanied by nausea and vomiting. On November 29, alanine amino transferase (ALT) concentration suddenly increased, while renal function and coagulation remained normal. Then we decided to suspend favivpiravir administration. November 30, the patient underwent a second administration of convalescent plasma from a different donor. Eventually patient received melanocortin [<xref ref-type="bibr" rid="CR13">13</xref>] (a peptide for controlling &#x201C;cytokine storms&#x201D; and preventing vascular leakage syndrome) and steroids. The following day respiratory function gradually worsened and chest X-rays performed on December 2 showed bilateral interstitial pulmonary infiltrates (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). On December 3, the patient received ZMAb [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] a mixture of monoclonal antibody against EBOV glycoprotein. The administration was followed by a sharp reduction of the EBOV blood level. The same day due to progressive onset of severe respiratory failure the patient was moved to the intensive care unit (ICU).<fig id="Fig4"><label>Fig. 4</label><caption><p>Chest XR carried out on December 2 2014. SN= left side; the white square was added for patient&#x2019;s privacy protection </p></caption><graphic xlink:href="12879_2015_1169_Fig4_HTML" id="MO4"/></fig></p>
        </sec>
        <sec id="Sec6">
          <title>Admission in ICU</title>
          <p>The patient was cared for in the ICU between December 4 and 11. This unit meets requirement for high level bio-containment [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Soon after admission, he underwent mechanical ventilation and a three-way central venous catheter (CVC) was inserted into the right internal jugular vein. A urinary catheter and a naso-gastric tube were also inserted.</p>
          <p>While intubated, the patient underwent lung ultrasounds (Nanomaxx Sonosite&#xAE;) according to Bedside Lung Ultrasound in Emergency (BLUE) protocol [<xref ref-type="bibr" rid="CR17">17</xref>]. Pleural effusion and pneumothorax were ruled out, but the presence of up to four B-lines in all the standard points suggested a significant lung interstitial involvement. A progressive bilateral reduction in the number of B-lines, initially in the upper and lower BLUE points, and later in the posterolateral alveolar or pleural syndromes point, was observed during the ICU stay.</p>
          <p>On December 5, he received a second dose of ZMAb followed by a second sharp decrease of EBOV viremia. On December 6, due to severe non-bloody diarrhea, a rectal fecal collector (Flexiseal&#xAE; ConvaTec) was placed. On December 7, due to persisting fever another malaria test (PCR) was performed which yielded a positive results for <italic>P. vivax</italic> infection. Therefore anti-malaria therapy was started. On December 9, the patient underwent a bronchial aspirate; PCR on bronchial aspirate fluids evidenced a viral load of 6.88 Log copies of EBOV RNA/ml. All PCRs for other viral and bacterial respiratory pathogens were negative (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>). On December 10, the patient was extubated and moved to the medical isolation unit one day later.</p>
        </sec>
        <sec id="Sec7">
          <title>Recovery and discharge</title>
          <p>After readmission to the medical isolation unit the clinical conditions gradually improved. On December 11, all antimicrobials were suspended considering the improvement of general conditions and persistent lack of positive cultural and molecular test for bacteria and fungi (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Since December 14 fever completely disappeared. On December 17, CVC, urinary catheter and rectal fecal collector were also removed. On December 21, the patient completely recovered.</p>
          <p>A progressive increase of the anti-EBOV IgM titer was observed from December 11, reaching a peak of 1:160 on December 25. The anti-EBOV IgG titer was stably at 1:160 until December 25, presumably as the result of convalescent plasma administration, and eventually increased until discharge. The patients was discharged on January 2 after that two consecutive negative EBOV PCR assay results from blood, urine, sweat (axillary swab) and stool were obtained (see Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).</p>
        </sec>
      </sec>
      <sec id="Sec8">
        <title>Therapeutic intervention</title>
        <sec id="Sec9">
          <title>General supportive therapy</title>
          <p>The patient received 4-5&#xA0;L/day of intravenous hydration with crystalloid solution since admission for 18&#xA0;days. The amount and composition of the solution were based on the daily plasma determination of electrolytes, venous pH and daily fluid output. Between November 28 and December 4, he received parenteral nutrition and, eventually, enteral nutrition between December 5 and 11 (approximately 2000 kCal/day). Between December 4 and 11, he received norepinephrine (0.05 mcg/kg/min) and furosemide (20&#xA0;mg tid).</p>
        </sec>
        <sec id="Sec10">
          <title>Antimicrobials</title>
          <p>The patient received empiric antibiotic treatment for 18&#xA0;days since admission. On November 25, he started ceftriaxone (2000&#xA0;mg daily) and oral levofloxacin (500&#xA0;mg bid). On November 28, ceftriaxone and levofloxacin were stopped due to the onset of severe diarrhea and increase of liver enzymes. Meropenem (1000&#xA0;mg tid i.v.) plus metronidazole (500&#xA0;mg qid i.v.) were started. On December 4, due to the persistence of fever and diarrhea, meropenem and metronidazole were discontinued and anidulafungin (200&#xA0;mg as a loading dose and then 100&#xA0;mg daily i.v.), piperacillin/tazobactam (4500&#xA0;mg qid i.v.), linezolid (600&#xA0;mg bid i.v.) and oral vancomycin (125&#xA0;mg qid) were started. Oral vancomycin was discontinued after a negative <italic>Clostridium difficile</italic> PCR assay on stools. On December 9, piperacillin/tazobactam and linezolid were discontinued, and metronidazole (500&#xA0;mg qid i.v.) was started.</p>
        </sec>
        <sec id="Sec11">
          <title>Anti-malarial therapy</title>
          <p>Anti-malarial therapy with chloroquine (600&#xA0;mg time 0 and then 300&#xA0;mg after 6, 24 and 48&#xA0;h) was given through a nasogastric tube. Primaquine was prescribed for future use after G6PDH determination following discharge.</p>
        </sec>
        <sec id="Sec12">
          <title>Melanocortin</title>
          <p>Melanocortin (TCS 10) [<xref ref-type="bibr" rid="CR13">13</xref>] was administered to prevent plasma leakage syndrome; two 10&#xA0;mg i.v. bolus 1&#xA0;h apart from each other, followed by a 6&#xA0;h continuous infusion of 50&#xA0;mg in 60&#xA0;ml of 0.9&#xA0;% NaCl solution.</p>
        </sec>
        <sec id="Sec13">
          <title>Favipiravir</title>
          <p>The oral RNA polymerase inhibitor favipiravir [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>] was administered orally for four days: loading dose in 3 fractionated doses (2400&#xA0;mg followed by 2400&#xA0;mg and then 1200&#xA0;mg), then 1200&#xA0;mg bid (cumulative dose 9,600&#xA0;mg).</p>
        </sec>
        <sec id="Sec14">
          <title>Convalescent plasma</title>
          <p>The first course of convalescent plasma consisted in a 250&#xA0;ml unit of a compatible blood group plasma to be administered with paracetamol and clorfenamine premedication. Due to insurgence of an adverse reaction oxygen therapy (50&#xA0;% Fi O2) and 500&#xA0;mg hydrocortisone plus clorfenamine 10&#xA0;mg were given i.v. infusion for 2 subsequent days.</p>
          <p>The second course of convalescent plasma consisted in a 250&#xA0;ml unit of a compatible blood group plasma from a different donor that was administered after premedication with paracetamol, clorfenamine and 500&#xA0;mg metylprednisolone. In this case no adverse reaction was reported.</p>
        </sec>
        <sec id="Sec15">
          <title>ZMAb</title>
          <p>Monoclonal antibodies were diluted, filtered with a 0.22&#xA0;&#x3BC;m filter and topped with 0.9&#xA0;% NaCl solution to a final volume of 1000&#xA0;ml. After premedication with 1&#xA0;mg/kg methyl prednisolone, ZMAb was infused in 12-15&#xA0;h via a peripheral line. No adverse reactions were observed.</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>We reported the case of a 50-year-old Italian physician with severe EVD due to EBOV Makona variant, complicated with severe interstitial pneumonia and <italic>P. vivax</italic> co-infection. He received prompt fluid replacement and electrolyte supplementation to prevent volume depletion, metabolic disorders and hypovolemic shock [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. He was finally discharged in good clinical conditions 39&#xA0;days after admission.</p>
      <p>Upon admission, the patient presented with severe lymphopenia and moderate low platelet count compatible with EBOV infection [<xref ref-type="bibr" rid="CR23">23</xref>] and P<italic>. vivax</italic> co-infection. On day 5 after admission, a sudden and sharp increase of WBC and platelets occurred, likely due to exogenous steroid administration and to melanocortin-induced endogenous glucocorticoid production [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      <p>Severe interstitial lung involvement was the main complication. Chest X-rays, lung ultrasounds and the high EBOV RNA concentration in the bronchial aspirate were strongly suggestive of EBOV-related interstitial pneumonia. Other authors reported respiratory failure in EVD possibly due to vascular leakage [<xref ref-type="bibr" rid="CR7">7</xref>] and transfusion related acute lung injury (TRALI) [<xref ref-type="bibr" rid="CR8">8</xref>]. However, we believe that vascular leakage was unlikely in this case because of the lack of both multi-organ involvement and coagulation abnormalities, that characterize vascular leakage syndrome [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In addition the presence of high EBOV RNA load in the lower respiratory tract secretions, in the absence of detection of other common respiratory pathogens, supports the hypothesis that EBOV could have directly contributed to the lung damage. In fact, it is unlikely that the EBOV RNA detected in bronchial aspirate fluids could represent a trivial result of spill over from the blood compartment, eventually accompanied by delayed clearance, since the concomitant blood sample showed barely detectable EBOV RNA, and the blood concentration in the previous 3&#xA0;days was 2.58-3.29 Log lower than the concentration in the bronchial aspirate. The most likely explanation for these findings is that the virus actually replicated into the lower respiratory tract. Noteworthy, direct viral involvement in lung injury has been already suggested in patients who received care in the USA [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, the hypothesis that the EBOV can actually replicate into lungs is supported by a recently published review which collect results of post mortem examinations from 89 cases of fatal filoviral infections in humans (24 of which with EBOV). This analysis provides evidence for viral replication in lungs by demonstrating viral antigens in several lung tissues and the presence of EBOV nucleic acids in resident macrophages [<xref ref-type="bibr" rid="CR26">26</xref>]. Whether the <italic>P. vivax</italic> co-infection might have contributed to the lung injury can be hardly ascertained; however, acute respiratory distress syndrome is a frequent clinical feature in the rare circumstance of fatal <italic>P.vivax</italic> infection [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
      <p>In our opinion, mechanical ventilation was crucial for survival in our patient because supported respiratory function and prevented muscular exhaustion, which allowed the patient to recover from the acute lung injury. This underlines that prompt access to advanced life support provides a substantial clinical benefit in EVD [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
      <p>Despite 3 negative malaria antigen assays, the patient eventually tested positive in a PCR assay for <italic>P. vivax</italic>. Malaria co-infection was recently reported in an EVD patient who received care in the USA [<xref ref-type="bibr" rid="CR9">9</xref>]. Our experience highlights that malaria antigen assays may offer an incomplete diagnostic picture leading to sub-optimal clinical management. Consequently, patients with EVD returning from areas endemic for malaria should receive empirical malaria treatment if neither molecular or microscopy assays are available or if concerns on malaria are raised.</p>
      <p>Our patient also received empirical therapy against bacteria, fungi and intestinal protozoa. Severe bacterial super-infection has already been reported in subjects who received care for EVD in Europe [<xref ref-type="bibr" rid="CR6">6</xref>]. At present, there is no definitive evidence to predict the actual risk of microbial super-infection in EVD patients. Nevertheless, we feel that the use of anti-infective drugs is a prudent approach. In fact, EVD patients may develop severe infective complications as the consequence of bacteria translocation from the gut [<xref ref-type="bibr" rid="CR6">6</xref>], from equipment used for parenteral nutrition [<xref ref-type="bibr" rid="CR29">29</xref>] or co-infection with tropical intestinal protozoa [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
      <p>Our patient received three different experimental antiviral treatment, including favipiravir, convalescent plasma and ZMAb.</p>
      <p>Favipiravir was given for 4&#xA0;days. During this time, the patient experienced worsening of gastrointestinal symptoms, and an increased of ALT and bilirubin levels. This report provides no evidence of any causative association between favipiravir and either potential adverse events or viral load variation. In particular, gastrointestinal and liver abnormalities may be the consequence of <italic>P. vivax</italic> and EBOV infections. In fact, data from uncontrolled studies in EBOV-confirmed that patients did not report significant hepatic or gastrointestinal toxicity for similar favipiravir dosages but fail in providing any conclusive evidence on drugs efficacy [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p>The two administrations of convalescent plasma were associated with a decrease viral load of 2.10 and 0.80 Log RNA copies/ml, respectively. The adverse event after the first plasma administration may have been due to an immune reaction to factors of the unknown donor and/or the lack of premedication with steroids. The possible influence of such adverse reaction on lung injury cannot be ruled out. Nevertheless, transfusion related acute lung injury (TRALI) could have hardly had a primary role. In fact, TRALI is an acute event which occurs within 6&#xA0;h after transfusion [<xref ref-type="bibr" rid="CR33">33</xref>]. In contrast our patients had lung function significantly worsened only since December 3, this is 7 and 3&#xA0;days after the first and second convalescent plasma transfusion, respectively. Beside the two plasma donors (one of whom was a female) had no history of blood transfusions or previous pregnancies, which reduce possibility of TRALI [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
      <p>Administration of ZMAb [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] was temporally associated with a sharp and sustained decay of plasma viral load. As the increase of IgM and IgG was observed after the start of viremia decay, it is unlikely that the endogenous antibody response could be responsible for the observed decay of EBOV RNA, although the administration of convalescent plasma is a major confounder. The potential beneficial effect of monoclonal antibody therapy against EVD was reported in a recent experience describing the clinical management of few EVD patients treated with ZMapp (a similar, though not identical compound) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Interestingly, monoclonal antibody therapy against EBOV is one of only two clinical interventions capable of decreasing viral loads and significantly reduce the mortality of non-human primates infected with EBOV in controlled conditions [<xref ref-type="bibr" rid="CR34">34</xref>]. Although, no causal association between administration of ZMAb and the patient&#x2019;s outcome can be inferred; in fact, the viral decay load might have been coincidental rather than due to the ZMAb administration.</p>
    </sec>
    <sec id="Sec17" sec-type="conclusions">
      <title>Conclusion</title>
      <p>This report describes the successful management of a patient with severe EVD in a setting with high healthcare standards. Several issues emerge from our experience. Firstly, fluid replacement and advanced life support with mechanical ventilation were pivotal for the patient&#x2019;s recovery, and in our opinion, all patients with EVD should have access to this level of care. Secondly, it is prudent to start empirical therapy for malaria in the absence of reliable testing, such as PCR assays. Finally, similarly to other individual experiences, we observed a close temporal association between administration of ZMAb and viral load decay, suggesting that clinical and translational research on these new promising molecules should be prioritize.</p>
    </sec>
    <sec id="Sec18">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images.</p>
      <p>The INMI&#x2019;s Institutional Ethical Board assessed the criteria for access to experimental drugs and invasive procedures, approved informed consent form and analyzed ethical issues and possible solutions to minimize the physical and psychological harm for the patient. The patient signed an informed consent for any single procedure or treatment performed, after thoroughly explanation of reasonably anticipated benefits and potential hazards of intervention.</p>
      <p>Emergency Use Authorization for investigational new drugs was issued by the Italian Drug Agency (AIFA), the authority entitled to approve medical agents to be used for therapy of disease when they are not the standard of care or supported by research that proves their safety.</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec27">
          <title>Additional files</title>
          <p>
            <media position="anchor" xlink:href="12879_2015_1169_MOESM1_ESM.docx" id="MOESM1">
              <label>Additional file 1:</label>
              <caption>
                <p>
<bold>Laboratory methods.</bold>
</p>
              </caption>
            </media>
            <media position="anchor" xlink:href="12879_2015_1169_MOESM2_ESM.gif" id="MOESM2">
              <label>Additional file 2:</label>
              <caption>
                <p>
<bold>Clinical course timeline.</bold>
</p>
              </caption>
            </media>
            <media position="anchor" xlink:href="12879_2015_1169_MOESM3_ESM.docx" id="MOESM3">
              <label>Additional file 3:</label>
              <caption>
                <p>
<bold>Person and institution involved in the organization and management of the patient.</bold>
</p>
              </caption>
            </media>
          </p>
        </sec>
      </app>
    </app-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>EBOV</term>
          <def>
            <p>Ebola virus Makona variant</p>
          </def>
        </def-item>
        <def-item>
          <term>EVD</term>
          <def>
            <p>Ebola virus disease</p>
          </def>
        </def-item>
        <def-item>
          <term>PCR</term>
          <def>
            <p>Polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>RNA</term>
          <def>
            <p>Ribonucleic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>P. vivax</italic>
          </term>
          <def>
            <p>
              <italic>Plasmodium vivax</italic>
            </p>
          </def>
        </def-item>
        <def-item>
          <term>ALT</term>
          <def>
            <p>Alanine amino transferase</p>
          </def>
        </def-item>
        <def-item>
          <term>ICU</term>
          <def>
            <p>Intensive care unit</p>
          </def>
        </def-item>
        <def-item>
          <term>CVC</term>
          <def>
            <p>Central venous catheter</p>
          </def>
        </def-item>
        <def-item>
          <term>mg</term>
          <def>
            <p>Milligrams</p>
          </def>
        </def-item>
        <def-item>
          <term>ml</term>
          <def>
            <p>Milliliters</p>
          </def>
        </def-item>
        <def-item>
          <term>tid</term>
          <def>
            <p>Ter in die (thrice time a day)</p>
          </def>
        </def-item>
        <def-item>
          <term>bid</term>
          <def>
            <p>Bis in die (twice a day)</p>
          </def>
        </def-item>
        <def-item>
          <term>qid</term>
          <def>
            <p>Quater in die (four times a day)</p>
          </def>
        </def-item>
        <def-item>
          <term>i.v.</term>
          <def>
            <p>Intravebeous</p>
          </def>
        </def-item>
        <def-item>
          <term>Log</term>
          <def>
            <p>Decimal logarithm</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interest</bold>
        </p>
        <p>Gary Kobinger holds a research grant from the Canadian Center for Security Sciences. From the National Institute of Health, in which funds were used to develop monoclonal antibody therapies against Ebola. All other authors declare no conflict of interest.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contribution</bold>
        </p>
        <p>SL, EN, NP and GI designed the study. NP and SL drafted the manuscript. NP, EN, MRC, ADC, MA, VP, FNL, NM, NS, GPK contributed to the diagnosis and treatment. GI reviewed and supervised the manuscript. All the authors approved the final version of the manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>This work has been supported by grants from Italian Ministry of Health (Ricerca Corrente and Ricerca Finalizzata). Preparedness for diagnostic activities was supported by QUANDHIP and EMLab Projects funded by EU DG SANCO and DEVCO respectively. Preparatory research activities were carried out also in the framework of PREDEMIC project (EU DG RTD).</p>
      <p>We gratefully acknowledge the generous assistance and valuable information provided to us by so many persons and Institutions that it is impossible to mention them all in a brief space and main listed in the attachment.</p>
      <p>We must, however, express special thanks to all staff of the Institute, who with his skill and commitment has allowed to continue all ordinary activities, also replacing colleagues engaged in the management of the case.</p>
      <p>Our sincere thanks to the dedicated staff of the Italian Air Force for their invaluable MEDEVAC of the patient from Sierra Leone.</p>
      <p>Finally, we would like to record our deep gratitude to the INMI&#x2019;s Institutional Ethical Board (IEB) who provided guidance to identify and resolve ethical dilemmas for management of this case (members of IEB are listed in the attachment).</p>
      <sec id="FPar1">
        <title>Members of the INMI EBOV Team</title>
        <p>Crisis unit: Nicola Petrosillo, Emanuele Nicastri, Francesco Nicola Lauria, Vincenzo Puro, Mario Antonini, Antonio Russo, Maria Rosaria Capobianchi, Antonino Di Caro, Paolo D&#x2019;Aprile, Antonella Petrecchia, Evangelo Boumis, Marco Gentile, Damiano Travaglini, Silvia Pittalis, Lorena Martini, Concetta Castilletti, Francesco Maria Fusco, Simone Lanini, Andrea Antinori, Giuseppe Ippolito, Valerio Fabio Alberti; Infectious Diseases Physicians: Nicola Petrosillo, Emanuele Nicastri, Nazario Bevilacqua, Evangelo Boumis, Stefania Cicalini, Pierangelo Chinello, Angela Corpolongo, Andrea Mariano, Fabrizio Taglietti, Laura Vincenzi, Telma Azevedo; Intensive Care Physicians: Mario Antonini, Ilaria Caravella, Gabriele Garotto, Luisa Marchioni, Micaela Maritti; Nurses: Gianni Battisti, Alessanda Coppola, Loredana De Marchis, Nicola De Marco, Fabio Di Gianbattista, Mario Guiducci, Daniela Imola, Antonio Marasco, Antonella Marzolini, Alessandro Mercuri, Paola Nieddu, Silvia Ondedei, Maurizio Vescovo, Laura Vitolo; Radiologists: Elisa Busi Rizzi; Hospital pharmacist: Silvia Murachelli; Virologists and microbiologists: Maria Rosaria Capobianchi, Antonino di Caro, Concetta Castilletti, Licia Bordi, Eleonora Lalle, Silvia Meschi, Daniele Lapa, Patrizia Marsella, Francesca Colavita, Roberta Chiappini, Antonio Mazzarelli, Serena Quartu, Chiara Agrati, Fabrizio Carletti, Federica Forbici, Maria Beatrice Valli, Isabella Abbate, Alessandra Amendola, Anna Rosa Garbuglia,Maria Grazia Paglia, Eugenio Bordi, Antonietta Toffoletti; Transport in high biocontainment: Gaetano Battisti, Marco Liguori; Engineering department: Paolo D&#x2019;Aprile, Raffaella Barbaro; Press Office: Lorella Salce, Daniela Renna, Simona Barbato, Paola Vaccaro, Francesco Bianchini.&#xA0;Additional file <xref rid="MOESM3" ref-type="media">3</xref> reports person and institution involved in the organization and management of the patient.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dye</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>WHO Ebola Response Team. Ebola virus disease in Western Africa--the first 9 months</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <issue>2</issue>
          <fpage>189</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1413936</pub-id>
          <pub-id pub-id-type="pmid">25564903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chevalier</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weil</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Joyner</surname>
              <given-names>SN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Centers for Disease Control and Prevention (CDC). Ebola virus disease cluster in the United States--Dallas County, Texas, 2014</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2014</year>
          <volume>63</volume>
          <issue>46</issue>
          <fpage>1087</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">25412069</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parra</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Salmer&#xF3;n</surname>
              <given-names>OJ</given-names>
            </name>
            <name>
              <surname>Velasco</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The first case of Ebola virus disease acquired outside Africa</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>371</volume>
          <issue>25</issue>
          <fpage>2439</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1412662</pub-id>
          <pub-id pub-id-type="pmid">25409262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Infectious diseases. When Ebola protection fails</article-title>
          <source>Science</source>
          <year>2014</year>
          <volume>346</volume>
          <issue>6205</issue>
          <fpage>17</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1126/science.346.6205.17</pub-id>
          <pub-id pub-id-type="pmid">25278588</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Health worker critically ill, as Ebola exposures prompt flurry of medical evacuations. Center for Infectious Diseases Research and Policy (CIDRAP) Website. http://www.cidrap.umn.edu/news-perspective/2015/03/health-worker-critically-ill-ebola-exposures-prompt-flurry-medical. Updated March 16, 2015. Accessed on June 5, 2015</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreuels</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wichmann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Emmerich</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schmidt-Chanasit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Heer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kluge</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of severe Ebola virus infection complicated by gram-negative septicemia</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>371</volume>
          <issue>25</issue>
          <fpage>2394</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1411677</pub-id>
          <pub-id pub-id-type="pmid">25337633</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P et al Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2014. doi:10.1016/S0140-6736(14)62384-9</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mora-Rillo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arsuaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ram&#xED;rez-Olivencia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>de la Calle</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Borobia</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid</article-title>
          <source>Spain. Lancet Respir Med.</source>
          <year>2015</year>
          <volume>3</volume>
          <issue>7</issue>
          <fpage>554</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(15)00180-0</pub-id>
          <pub-id pub-id-type="pmid">26041403</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lyon</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Varkey</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Brantly</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Plyler</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>McElroy</surname>
              <given-names>AK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical care of two patients with Ebola virus disease in the United States</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>371</volume>
          <issue>25</issue>
          <fpage>2402</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1409838</pub-id>
          <pub-id pub-id-type="pmid">25390460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK et al. Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. Ann Intern Med. 2015. doi:10.7326/M15-0530</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">Biselli R, Lastilla M, Arganese F, Ceccarelli N, Tomao E, Manfroni P. The added value of preparedness for aeromedical evacuation of a patient with Ebola. Eur J Intern Med. 2015. doi:10.1016/j.ejim.2015.03.010</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">Di Caro A, Puro V, Fusco FM, Capobianchi MR, Lanini S, Lauria FN et al. The added value of long-lasting preparedness for the management of a patient with Ebola. Eur J Intern Med. 2015. doi:10.1016/j.ejim.2015.03.005</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noera</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lamarra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guarini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bertolini</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Survival rate after early treatment for acute type-A aortic dissection with ACTH-(1-24)</article-title>
          <source>Lancet</source>
          <year>2001</year>
          <volume>358</volume>
          <issue>9280</issue>
          <fpage>469</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(01)05631-8</pub-id>
          <pub-id pub-id-type="pmid">11513913</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Audet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Kobinger</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus</article-title>
          <source>Sci Rep.</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>6881</fpage>
          <pub-id pub-id-type="doi">10.1038/srep06881</pub-id>
          <pub-id pub-id-type="pmid">25375093</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J et al. MAbs and Ad-vectored IFN-&#x3B1; therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5(207):207ra143. doi:10.1126/scitranslmed.3006605</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brouqui</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Puro</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fusco</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Bannister</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schilling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Follin</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease</article-title>
          <source>Lancet Infect Dis</source>
          <year>2009</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>301</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(09)70070-2</pub-id>
          <pub-id pub-id-type="pmid">19393960</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lichtenstein</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mezi&#xE8;re</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The BLUE points: three standardized points used in the BLUE-protocol for ultrasound assessment of the lung in acute respiratory failure</article-title>
          <source>Crit Ultrasound J</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>109</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="doi">10.1007/s13089-011-0066-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Clercq</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Ebola virus (EBOV) infection: Therapeutic strategies</article-title>
          <source>Biochem Pharmacol</source>
          <year>2015</year>
          <volume>93</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2014.11.008</pub-id>
          <pub-id pub-id-type="pmid">25481298</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Mentr&#xE9; F, Taburet AM, Guedj J, Anglaret X, Ke&#xEF;ta S, de Lamballerie X et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2014. doi:10.1016/S1473-3099(14)71047-3</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="other">Sissoko D, Anglaret X, Malvy D Abdoul, Beavogui H, Gunther S, Shepherd S et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Conference on Retroviruses and Opportunistic Infections: Seattle, WA. February 23&#x2013;26, 2015. 103-ALB</mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Falasca L, Agrati C, Petrosillo N, Di Caro A, Capobianchi MR, Ippolito G et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015. doi: 10.1038/cdd.2015.67</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamontagne</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cl&#xE9;ment</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>WA</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Doing Today's Work Superbly Well - Treating Ebola with Current Tools</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>371</volume>
          <fpage>1565</fpage>
          <lpage>1566</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMp1411310</pub-id>
          <pub-id pub-id-type="pmid">25251518</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spiropoulou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rollin</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro</article-title>
          <source>Virology</source>
          <year>2007</year>
          <volume>364</volume>
          <issue>1</issue>
          <fpage>45</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1016/j.virol.2007.02.017</pub-id>
          <pub-id pub-id-type="pmid">17391724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catania</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The melanocortin system in leukocyte biology</article-title>
          <source>J Leukoc Biol</source>
          <year>2007</year>
          <volume>81</volume>
          <issue>2</issue>
          <fpage>383</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1189/jlb.0706426</pub-id>
          <pub-id pub-id-type="pmid">17041004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baluna</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vitetta</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title>Vascular leak syndrome: a side effect of immunotherapy</article-title>
          <source>Immunopharmacology</source>
          <year>1997</year>
          <volume>37</volume>
          <issue>2-3</issue>
          <fpage>117</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1016/S0162-3109(97)00041-6</pub-id>
          <pub-id pub-id-type="pmid">9403331</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martines</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Greer</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Rollin</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Zaki</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses</article-title>
          <source>J Pathol</source>
          <year>2015</year>
          <volume>235</volume>
          <issue>2</issue>
          <fpage>153</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1002/path.4456</pub-id>
          <pub-id pub-id-type="pmid">25297522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Londhe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ganeriwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>deSouza</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Study of clinical profile of acute respiratory distress syndrome and acute lung injury in Plasmodium vivax malaria</article-title>
          <source>J Vector Borne Dis</source>
          <year>2014</year>
          <volume>51</volume>
          <issue>4</issue>
          <fpage>339</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">25540968</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ippolito</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Feldmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lanini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vairo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Di Caro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Capobianchi</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Viral hemorrhagic fevers: advancing the level of treatment</article-title>
          <source>BMC Med.</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>31</fpage>
          <pub-id pub-id-type="doi">10.1186/1741-7015-10-31</pub-id>
          <pub-id pub-id-type="pmid">22458265</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dissanaike</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shelton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Warner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>O'Keefe</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>The risk for bloodstream infections is associated with increased parenteral caloric intake in patients receiving parenteral nutrition</article-title>
          <source>Crit Care</source>
          <year>2007</year>
          <volume>11</volume>
          <issue>5</issue>
          <fpage>R114</fpage>
          <pub-id pub-id-type="doi">10.1186/cc6167</pub-id>
          <pub-id pub-id-type="pmid">17958913</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herbinger</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Perona</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>L&#xF6;scher</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiological, clinical, and diagnostic data on intestinal infections with Entamoeba histolytica and Entamoeba dispar among returning travelers</article-title>
          <source>Infection</source>
          <year>2011</year>
          <volume>39</volume>
          <issue>6</issue>
          <fpage>527</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1007/s15010-011-0155-z</pub-id>
          <pub-id pub-id-type="pmid">21717146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="other">Mentr&#xE9; F, Taburet AM, Guedj J, Anglaret X, Ke&#xEF;ta S, de Lamballerie X et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2014. doi: 10.1016/S1473-3099(14)71047-3</mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="other">Lanini S, Zumla A, Ioannidis JP, Caro AD, Krishna S, Gostin L et al. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lancet Infect Dis. 2015. doi: 10.1016/S1473-3099(15)70106-4.</mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Popovsky</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ambruso</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Holness</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Kopko</surname>
              <given-names>PM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review</article-title>
          <source>Crit Care Med</source>
          <year>2005</year>
          <volume>33</volume>
          <issue>4</issue>
          <fpage>721</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1097/01.CCM.0000159849.94750.51</pub-id>
          <pub-id pub-id-type="pmid">15818095</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Audet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fernando</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bello</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pillet</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb</article-title>
          <source>Sci Rep.</source>
          <year>2013</year>
          <volume>3</volume>
          <fpage>3365</fpage>
          <pub-id pub-id-type="pmid">24284388</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
